Symphogen A/S

Creating novel antibody therapeutics

[ICBI Georgetown @ICBI_Georgetown]

Acquired resistance to single MET antibody in vivo can be overcome by the MET antibody mixture Sym015: breaking cancer research from a collaboration btwn @ICBI_Georgetown @SymphogenAS @GeorgeMasonU @uni_copenhagen @Rigshospitalet https://t.co/TQZ2EI1Pov @AACR #hopeforthecure

[Philip Hemme @PhilipHemme]

Impressive list: The Top 10 Biotech Companies in Copenhagen, Denmark https://t.co/2BLcNLYGv8 via @Labiotech_eu @DANSKBIOTEK @mediconvalley @Genmab @Novozymes @SymphogenAS @AscendisUK @ZealandPharma @BavarianNordic @GalectoBiotech #iobiotech @Orphazyme_AS

[Symphogen A/S @SymphogenAS]

Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses
https://t.co/aDxJehRbuH